We are live on
!
Find out more
Lexicon Pharmaceuticals
LXRX
LXRX
104 hedge funds and large institutions have $354M invested in Lexicon Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 37 increasing their positions, 34 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
31% more call options, than puts
Call options by funds: $374K | Put options by funds: $286K
26% more capital invested
Capital invested by funds: $280M → $354M (+$74M)
9% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 34
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.68% less ownership
Funds ownership: 77.83% → 77.15% (-0.68%)
1% less funds holding
Funds holding: 105 → 104 (-1)
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
Holders
104
Holders Change
-1
Holders Change %
-0.95%
% of All Funds
1.66%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
37
Reduced
34
Closed
15
Calls
$374K
Puts
$286K
Net Calls
+$88K
Net Calls Change
-$139K
Top Buyers
| 1 |
Axa
Paris,
France
|
+$769K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$702K |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$582K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$269K |
| 5 |
Natixis Advisors
Boston,
Massachusetts
|
+$201K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$2.64M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.9M |
| 3 |
BlackRock
New York
|
-$448K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$442K |
| 5 |
D.E. Shaw & Co
New York
|
-$314K |
